Lomustine study for MGMT methylated glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding lomustine chemotherapy to standard treatment for people with a specific type of glioblastoma that has a methylated MGMT gene. It aims to see if this combination helps control the tumor better and improves survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a glioblastoma or gliosarcoma that is IDH wild type and MGMT methylated.
- You are between 18 and 70 years old.
- Your overall health is good, allowing you to carry out daily activities (WHO performance status 0-2).
- You have not had another cancer within the last 3 years (unless it was treated and cured).
- You have not received chemotherapy or radiation that involved your head before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the usual treatment (radiation plus a chemotherapy drug called temozolomide) with the same treatment plus an extra drug called lenvatinib. The goal is to see if adding lenvatinib helps people with a certain type of glioblastoma live longer or keep the tumor from growing back.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This trial tests whether adding a new drug, WSD0922-FU, to standard chemotherapy (temozolomide) works better than temozolomide alone for a specific type of glioblastoma that has an EGFR mutation. It is for patients who have completed radiation and temozolomide together but haven't started maintenance temozolomide yet.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.